Quoin Pharmaceuticals, Ltd.(QNRX)Earnings, Financials & Key Ratios
QNRX•NASDAQ
$6.43
$10M mkt cap·Price updated May 6, 2026
AboutQuoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.Show more
- Revenue$0
- EBITDA-$9M-1.7%
- Net Income-$9M-3.2%
- EPS (Diluted)-66.85+80.2%
- ROE-120.55%+9.3%
- ROIC-161.61%+10.3%
QNRX Key Insights
Quoin Pharmaceuticals, Ltd. (QNRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
QNRX Price & Volume
Quoin Pharmaceuticals, Ltd. (QNRX) stock price & volume — 10-year historical chart
Loading chart...
QNRX Growth Metrics
Quoin Pharmaceuticals, Ltd. (QNRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-59.02%
Return on Capital
10 Years12.8%
5 Years-108.87%
3 Years-102.89%
Last Year-94.73%
QNRX Peer Comparison
Quoin Pharmaceuticals, Ltd. (QNRX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 |
Compare QNRX vs Peers
Quoin Pharmaceuticals, Ltd. (QNRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QNRX Income Statement
Quoin Pharmaceuticals, Ltd. (QNRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | -280K | 0 | -280K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | 100% | - | 100% | - | - | - | - | - | - |
| Cost of Goods Sold | 89.13K | 104.22K | 125.72K | 227.06K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | -31.83% | - | -44.9% | - | - | - | - | - | - | - |
| Gross Profit | -369.13K▲ 0% | -104.22K▲ 71.8% | -405.72K▼ 289.3% | -227.06K▲ 44.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | 131.83% | - | 144.9% | - | - | - | - | - | - | - |
| Gross Profit Growth % | -1920.31% | 71.77% | -289.28% | 44.04% | 100% | - | - | - | - | - |
| Operating Expenses | 16.22M | 10.1M | 16.22M | 1.56M | 1.67M | 6.06M | 9.26M | 9.38M | 9.53M | 14.18M |
| OpEx % of Revenue | -5794.29% | - | -5794.29% | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.97M | 4.2M | 7.97M | 1.51M | 1.43M | 4.5M | 6.58M | 6.07M | 5.93M | 6.4M |
| SG&A % of Revenue | -2845.71% | - | -2845.71% | - | - | - | - | - | - | - |
| Research & Development | 8.26M | 5.89M | 8.26M | 45.65K | 244.16K | 1.56M | 2.67M | 3.31M | 3.6M | 7.78M |
| R&D % of Revenue | -2948.57% | - | -2948.57% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 15.32M▲ 0% | 10.17M▼ 33.6% | 15.32M▲ 50.6% | -1.56M▼ 110.2% | -1.67M▼ 7.0% | -6.06M▼ 263.0% | -9.26M▼ 52.7% | -9.38M▼ 1.3% | -9.53M▼ 1.6% | -14.18M▲ 0% |
| Operating Margin % | -5470.36% | - | -5470.36% | - | - | - | - | - | - | - |
| Operating Income Growth % | 689.46% | -33.59% | 50.58% | -110.19% | -7.02% | -263.04% | -52.7% | -1.3% | -1.6% | - |
| EBITDA | 15.41M | 10.28M | 15.44M | -1.33M | -1.57M | -5.96M | -9.15M | -9.27M | -9.43M | -14.08M |
| EBITDA Margin % | -5502.19% | - | -5515.26% | - | - | - | - | - | - | - |
| EBITDA Growth % | 697.09% | -33.3% | 50.28% | -108.63% | -17.45% | -280.52% | -53.62% | -1.32% | -1.66% | -52.32% |
| D&A (Non-Cash Add-back) | 89.13K | 104.22K | 125.72K | 227.06K | 104.04K | 104.04K | 104.04K | 103.71K | 100K | 100K |
| EBIT | -3.99M | -7.91M | -5.59M | -4.31M | -1.67M | -20.37M | -8.67M | -9.38M | -9.53M | -14.1M |
| Net Interest Income | 0 | 0 | 0 | -412.29K | -1.19M | -1.09M | -618.34K | 694.61K | 558.49K | 359.6K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 95.75K | 694.61K | 558.49K | 359.6K |
| Interest Expense | 0 | 0 | 0 | 412.29K | 1.19M | 1.09M | 714.08K | 0 | 0 | 0 |
| Other Income/Expense | 237.07K | -1.06M | 2.54M | 0 | -425.35K | -15.4M | -123.79K | 691.93K | 565.99K | 407.79K |
| Pretax Income | 15.32M▲ 0% | 10.17M▼ 33.6% | 15.32M▲ 50.6% | -1.56M▼ 110.2% | -2.1M▼ 34.3% | -21.46M▼ 924.3% | -9.38M▲ 56.3% | -8.69M▲ 7.4% | -8.96M▼ 3.2% | -13.77M▲ 0% |
| Pretax Margin % | -5470.36% | - | -5470.36% | - | - | - | - | - | - | - |
| Income Tax | 147.94K | -1.17M | -161.14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.97% | -11.47% | -1.05% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 15.32M▲ 0% | 10.17M▼ 33.6% | 15.32M▲ 50.6% | -1.56M▼ 110.2% | -2.1M▼ 34.3% | -21.46M▼ 924.3% | -9.38M▲ 56.3% | -8.69M▲ 7.4% | -8.96M▼ 3.2% | -13.77M▲ 0% |
| Net Margin % | -5470.36% | - | -5470.36% | - | - | - | - | - | - | - |
| Net Income Growth % | 685.12% | -33.59% | 50.58% | -110.19% | -34.28% | -924.29% | 56.29% | 7.41% | -3.18% | -58.23% |
| Net Income (Continuing) | -4M | -7.91M | -5.59M | -1.56M | -2.1M | -21.46M | -9.38M | -8.69M | -8.96M | -13.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 10084.00▲ 0% | 5450.81▼ 45.9% | 7100.73▲ 30.3% | -440.29▼ 106.2% | -88.10▲ 80.0% | -28543.20▼ 32298.6% | -22.97▲ 99.9% | -337.47▼ 1369.2% | -66.85▲ 80.2% | -23.41▲ 0% |
| EPS Growth % | 578.15% | -45.95% | 30.27% | -106.2% | 79.99% | -32298.64% | 99.92% | -1369.18% | 80.19% | -59.02% |
| EPS (Basic) | 10084.00 | 5450.81 | 7100.73 | -440.29 | -88.10 | -28543.20 | -22.97 | -337.47 | -66.85 | - |
| Diluted Shares Outstanding | 1.52K | 1.87K | 2.16K | 3.54K | 20.02K | 1.6K | 403.88K | 25.74K | 133.96K | 588.17K |
| Basic Shares Outstanding | 1.52K | 1.87K | 2.16K | 3.54K | 20.02K | 1.6K | 403.88K | 25.74K | 133.96K | 588.17K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
QNRX Balance Sheet
Quoin Pharmaceuticals, Ltd. (QNRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.42M | 8.22M | 4.98M | 5.38M | 465.17K | 8.2M | 13.37M | 11.29M | 14.93M | 6.02M |
| Cash & Short-Term Investments | 8.04M | 7.99M | 4.77M | 5.24M | 323.83K | 7.48M | 12.85M | 10.69M | 14.06M | 5.41M |
| Cash Only | 1.63M | 3.96M | 4.77M | 5.24M | 323.83K | 7.48M | 2.86M | 2.4M | 3.62M | 1.83M |
| Short-Term Investments | 6.41M | 4.03M | 0 | 0 | 0 | 0 | 9.99M | 8.29M | 10.43M | 3.58M |
| Accounts Receivable | 172.01K | 70.57K | 57.8K | 77.3K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | -224.22 | - | -75.35 | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 141.34K | 0 | 0 | 32.58K | 0 | 0 |
| Total Non-Current Assets | 393.12K | 524.83K | 538.7K | 794.73K | 912.65K | 1.16M | 1.09M | 883.33K | 783.33K | 408.33K |
| Property, Plant & Equipment | 356.75K | 387.14K | 413.19K | 672.55K | 1.94M | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | -0.78x | - | -0.68x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 1.02M | 912.65K | 808.6K | 704.56K | 583.33K | 483.33K | 408.33K |
| Long-Term Investments | 36.38K | 137.69K | 125.51K | 122.18K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | -1.02K | -1.94M | 350K | 383.39K | 300K | 300K | 300K |
| Total Assets | 8.81M▲ 0% | 8.75M▼ 0.7% | 5.52M▼ 36.9% | 6.17M▲ 11.8% | 1.38M▼ 77.7% | 9.36M▲ 579.1% | 14.46M▲ 54.5% | 12.17M▼ 15.8% | 15.71M▲ 29.1% | 6.42M▲ 0% |
| Asset Turnover | -0.03x | - | -0.05x | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 156.59% | -0.7% | -36.87% | 11.76% | -77.68% | 579.11% | 54.52% | -15.83% | 29.09% | -70.74% |
| Total Current Liabilities | 905.51K | 1.18M | 1.31M | 1.05M | 7.99M | 4.58M | 3.53M | 3.58M | 4.18M | 5.76M |
| Accounts Payable | 348.95K | 490.55K | 237.37K | 45.74K | 0 | 923.24K | 605.6K | 526.52K | 905.7K | 1.86M |
| Days Payables Outstanding | 1.43K | 1.72K | 689.16 | 73.54 | - | - | - | - | - | - |
| Short-Term Debt | 15.07K | 0 | 0 | 114.65K | 1.21M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 541.49K | 127.32K | 1.07M | 637.81K | 0 | 373.6K | 0 | 0 | 0 | 416.94K |
| Current Ratio | 9.30x | 6.97x | 3.80x | 5.11x | 0.06x | 1.79x | 3.79x | 3.15x | 3.57x | 3.57x |
| Quick Ratio | 9.30x | 6.97x | 3.80x | 5.11x | 0.06x | 1.79x | 3.79x | 3.15x | 3.57x | 3.57x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 503.55K | 2.14M | 485.98K | 824.84K | 0 | 4.12M | 3.52M | 2.92M | 2.32M | 1.87M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 196K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 503.55K | 2.14M | 485.98K | 628.84K | 0 | 4.12M | 3.52M | 2.92M | 2.32M | 8.39M |
| Total Liabilities | 1.41M | 3.32M | 1.8M | 1.88M | 7.99M | 8.7M | 7.05M | 6.51M | 6.5M | 7.64M |
| Total Debt | 15.07K | 0 | 0 | 310.65K | 1.21M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -1.62M | -3.96M | -4.77M | -4.93M | 889.48K | -7.48M | -2.86M | -2.4M | -3.62M | -1.83M |
| Debt / Equity | 0.00x | - | - | 0.07x | - | - | - | - | - | -0.00x |
| Debt / EBITDA | 0.00x | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | -0.10x | -0.38x | -0.31x | - | - | - | - | - | - | 0.13x |
| Interest Coverage | - | - | - | -3.78x | -1.41x | -5.56x | -12.96x | - | - | - |
| Total Equity | 7.4M▲ 0% | 5.43M▼ 26.6% | 3.73M▼ 31.4% | 4.3M▲ 15.3% | -6.61M▼ 253.8% | 657.03K▲ 109.9% | 7.41M▲ 1027.3% | 5.66M▼ 23.5% | 9.2M▲ 62.5% | -1.21M▲ 0% |
| Equity Growth % | 174.27% | -26.63% | -31.39% | 15.29% | -253.82% | 109.94% | 1027.31% | -23.53% | 62.51% | -160.76% |
| Book Value per Share | 4876.01 | 2910.14 | 1727.38 | 1212.08 | -329.97 | 411.42 | 18.34 | 220.04 | 68.71 | -2.07 |
| Total Shareholders' Equity | 7.4M | 5.43M | 3.73M | 4.3M | -6.61M | 657.03K | 7.41M | 5.66M | 9.2M | -1.21M |
| Common Stock | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -9.28M | -18.42M | -22.49M | -29.2M | -6.61M | -28.07M | -37.52M | -46.2M | -55.17M | -66.62M |
| Treasury Stock | -2.45M | -2.71M | -2.52M | -2.73M | 0 | -2.93M | -2.93M | 0 | 0 | 0 |
| Accumulated OCI | 1.62M | 2.7M | 3.3M | 4.79M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QNRX Cash Flow Statement
Quoin Pharmaceuticals, Ltd. (QNRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.77M | -4.98M | -6.57M | -5.71M | -1.34M | -5.72M | -8.48M | -7.86M | -7.86M | -7.86M |
| Operating CF Margin % | 1345.36% | - | 2347.83% | - | - | - | - | - | - | - |
| Operating CF Growth % | -89.85% | -32.16% | -32.04% | 13.17% | 76.55% | -327.31% | -48.26% | 7.27% | 0.09% | -136.02% |
| Net Income | -4M | -7.91M | -5.59M | -4.72M | -2.1M | -21.46M | -9.38M | -8.69M | -9.01M | -13.77M |
| Depreciation & Amortization | 89.13K | 104.22K | 125.72K | 227.06K | 104.04K | 104.04K | 104.04K | 103.71K | 100K | 100K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 764.01K | 1.09M | 1.26M | 1.19M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 215.9K | 2.54M | -1.1M | -858.83K | 378.33K | 15.01M | 127.06K | -471.31K | -209.05K | 1.09M |
| Working Capital Changes | 54.89K | 245.71K | 233.92K | -358.69K | 274.36K | 632.33K | -94.35K | 95.2K | -2.14K | 645.96K |
| Change in Receivables | -274.19K | 131.68K | 11.96K | 108.05K | 60.19K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | -60.19K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 329.08K | 114.03K | 0 | 0 | 227.31K | 1.35M | -217.81K | 53.78K | 275.95K | 674.68K |
| Cash from Investing | -4.71M | 2.83M | 3.81M | -30.31K | -125K | -625K | -10.15M | 2.19M | -1.89M | 3.81M |
| Capital Expenditures | -330.64K | -74.53K | -182.46K | -34.52K | -125K | -625K | -250K | 0 | 0 | 0 |
| CapEx % of Revenue | -118.09% | - | -65.16% | - | - | - | - | - | - | - |
| Acquisitions | 24.83K | 0 | 0 | 1.68K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 2.99M | 3.83M | 0 | 0 | 0 | -14.88B | 5.64K | -9.68B | 869.3K |
| Cash from Financing | 9.13M | 4.43M | 3.55M | 6.14M | 1.79M | 13.5M | 14.01M | 5.22M | 10.97M | 5.64M |
| Debt Issued (Net) | 0 | 0 | 0 | -146.5K | 909.98K | 3.48M | -311.67K | -600K | -600K | -600K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | -142.33K | 0 | 1000K | 1000K | 1000K | 172.06K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -65.27M | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -14.82M | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 1.02M | 10.03M | 64.77M | -17.51K | -54.9K | 6.07M |
| Net Change in Cash | 653.45K▲ 0% | 2.32M▲ 255.7% | 809.83K▼ 65.2% | 476.13K▼ 41.2% | -4.92M▼ 1133.0% | 7.16M▲ 245.6% | -4.62M▼ 164.6% | -459.43K▲ 90.1% | 1.22M▲ 366.0% | -1.29M▲ 0% |
| Free Cash Flow | -4.1M▲ 0% | -5.05M▼ 23.3% | -6.76M▼ 33.7% | -5.74M▲ 15.0% | -1.46M▲ 74.5% | -6.35M▼ 333.5% | -8.73M▼ 37.6% | -7.86M▲ 9.9% | -7.86M▲ 0.1% | -10.74M▲ 0% |
| FCF Margin % | 1463.45% | - | 2413% | - | - | - | - | - | - | - |
| FCF Growth % | -97.99% | -23.32% | -33.71% | 15.01% | 74.51% | -333.52% | -37.6% | 9.92% | 0.09% | -21.46% |
| FCF per Share | -2699.38 | -2708.01 | -3132.31 | -1620.30 | -73.09 | -3973.13 | -21.62 | -305.52 | -58.65 | -58.65 |
| FCF Conversion (FCF/Net Income) | -0.25x | -0.49x | -0.43x | 3.66x | 0.64x | 0.27x | 0.90x | 0.91x | 0.88x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 393.61K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QNRX Key Ratios
Quoin Pharmaceuticals, Ltd. (QNRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 303.29% | 158.54% | 334.57% | -38.91% | - | -3266.6% | -232.68% | -132.92% | -120.55% | -334.42% |
| Return on Invested Capital (ROIC) | 307.22% | 210.18% | 5290.25% | - | - | - | - | -180.15% | -161.61% | -161.61% |
| Gross Margin | 131.83% | - | 144.9% | - | - | - | - | - | - | - |
| Net Margin | -5470.36% | - | -5470.36% | - | - | - | - | - | - | - |
| Debt / Equity | 0.00x | - | - | 0.07x | - | - | - | - | - | -0.00x |
| Interest Coverage | - | - | - | -3.78x | -1.41x | -5.56x | -12.96x | - | - | - |
| FCF Conversion | -0.25x | -0.49x | -0.43x | 3.66x | 0.64x | 0.27x | 0.90x | 0.91x | 0.88x | 0.78x |
| Revenue Growth | - | 100% | - | 100% | - | - | - | - | - | - |
QNRX Frequently Asked Questions
Quoin Pharmaceuticals, Ltd. (QNRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Quoin Pharmaceuticals, Ltd. (QNRX) grew revenue by 0.0% over the past year. Growth has been modest.
Quoin Pharmaceuticals, Ltd. (QNRX) reported a net loss of $13.8M for fiscal year 2024.
Dividend & Returns
Quoin Pharmaceuticals, Ltd. (QNRX) has a return on equity (ROE) of -120.6%. Negative ROE indicates the company is unprofitable.
Quoin Pharmaceuticals, Ltd. (QNRX) had negative free cash flow of $10.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More QNRX
Quoin Pharmaceuticals, Ltd. (QNRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates